Is Moderna or Pfizer Better? A Vaccine Comparison

Moderna consistently showed a small but measurable advantage over Pfizer in preventing COVID-19 infections and hospitalizations across multiple large studies, though both vaccines were highly effective. The gap between them was modest in absolute terms and widened as months passed after vaccination, suggesting Moderna’s protection held up longer. That effectiveness edge came with a trade-off: Moderna carried a higher risk of myocarditis, particularly in adolescents and young men. Choosing between them depends on which side of that balance matters more for a given person.

What Actually Differs Between the Two Shots

Moderna and Pfizer both use mRNA technology to instruct your cells to produce the SARS-CoV-2 spike protein, triggering an immune response. But the details of how they deliver that instruction differ in ways that likely explain the gap in both effectiveness and side effects. Moderna’s primary series contained about 100 micrograms of mRNA per dose, while Pfizer’s contained 30 micrograms. Moderna spaced its two doses 28 days apart versus Pfizer’s 21-day interval. The lipid nanoparticle shells wrapping the mRNA also had different compositions.¹

That three-fold difference in mRNA content is probably the single biggest factor behind the performance gap. A larger dose means more spike protein produced, a stronger initial immune response, and a higher starting point for antibodies before they begin their natural decline. The slightly longer interval between Moderna’s doses may also play a role, since the immune system generally builds a stronger memory response when it has more time between the initial prime and the booster.

How They Compared Against Infection and Hospitalization

The most rigorous head-to-head evidence came from studies in the U.S. Veterans Affairs healthcare system, which had the advantage of enormous sample sizes and detailed health records. One study published in the New England Journal of Medicine found that Pfizer recipients had roughly 1.2 extra documented infections per 1,000 people compared to Moderna recipients, along with about 0.55 extra COVID-related hospitalizations per 1,000 people. The difference in ICU admissions was smaller, around 0.10 per 1,000, and the difference in death was essentially zero.²

Those numbers are worth pausing on. At the level of “will I get infected,” Moderna offered a detectable advantage. At the level of “will I be hospitalized,” the advantage was still there but smaller. At the level of “will I die,” the two vaccines performed nearly identically. For most healthy adults, the practical upshot was that you were well protected either way. The gap between getting Moderna versus Pfizer was far smaller than the gap between getting either vaccine versus getting none at all.

It is also worth noting that the VA population skewed heavily male and older, which limits how directly these numbers translate to younger or female populations. Still, the direction of the finding, Moderna slightly outperforming Pfizer against infection and hospitalization, held up consistently across multiple studies and settings.

Why Moderna’s Advantage Grew Over Time

One of the more striking findings was that the gap between the two vaccines was not static. A large study tracking outcomes over progressively longer periods found that the differences in infection and hospitalization risk between Moderna and Pfizer grew as more time passed after vaccination.³ In other words, both vaccines’ protection waned, but Pfizer’s waned faster.

This pattern makes biological sense given the dose difference. If Moderna’s larger dose produced a higher peak antibody level, then even though both vaccines’ antibody levels declined at similar rates, Moderna recipients took longer to drop below the threshold where breakthrough infections become more likely. Think of it as two buckets of water with different starting levels draining at the same speed: the fuller bucket takes longer to empty.

The practical consequence was that the timing of your vaccination relative to a COVID wave mattered. If you had recently received either vaccine, protection was high regardless. But if you were five or six months out from your last dose, the Moderna recipients retained somewhat more residual protection. This waning dynamic was one of the key reasons booster doses became standard for both vaccines.

How Booster Doses Compared

When the updated bivalent boosters arrived, targeting both the original virus and the Omicron BA.4/BA.5 subvariants, the question of Moderna versus Pfizer came up again. A comparative effectiveness study of the bivalent boosters found that Moderna’s updated shot provided about a 10 percent relative advantage over Pfizer’s bivalent booster against COVID-related hospitalizations across the overall study population.⁴

A 10 percent relative difference is real but not dramatic. For someone deciding between a Moderna booster and a Pfizer booster sitting in front of them at a pharmacy, that gap was unlikely to justify waiting or traveling to find the other brand. Both bivalent boosters substantially reduced the risk of severe outcomes compared to having no booster at all. The overall message from the booster data was similar to the primary series: Moderna had a slight and consistent edge, but both worked well.

The booster landscape also introduced smaller dose comparisons. Moderna’s booster dose was 50 micrograms for much of the rollout, still higher than Pfizer’s 30 micrograms but lower than Moderna’s original 100-microgram primary dose. Even with this reduced dose, the pattern of a small Moderna advantage persisted, which reinforced the idea that the formulation differences, not just the raw mRNA quantity, played a role in the effectiveness gap.

The Myocarditis Trade-Off

Effectiveness is only half the picture. From early in the vaccine rollout, reports of myocarditis, an inflammation of the heart muscle, emerged as a rare but serious side effect of both mRNA vaccines. The risk was highest in younger males, particularly after the second dose. And it was consistently higher with Moderna than with Pfizer.

A systematic review and meta-analysis pooling data from multiple studies found that Moderna carried roughly a four-fold higher risk of myocarditis compared to Pfizer in adolescents and young adults. Individual studies varied, with some showing incidence rate ratios as high as 14.5 and others as low as the reverse direction, but the overall pooled estimate pointed clearly toward Moderna carrying more myocarditis risk in this age group.⁵

This is the reason many countries restricted Moderna for younger age groups or recommended Pfizer preferentially for adolescents and young adults. The absolute risk of vaccine-associated myocarditis remained low in both cases, and most cases resolved with supportive care, but a four-fold difference is meaningful when you are talking about heart inflammation in teenagers. For older adults, the myocarditis risk was much lower with either vaccine, and the effectiveness advantage of Moderna carried more weight relative to the smaller safety difference.

The myocarditis signal also appeared to be dose-dependent, which ties back to the formulation differences. A vaccine delivering more than three times as much mRNA is producing a more intense immune response, and that stronger response appears to come with a higher risk of the inflammatory overshoot that causes myocarditis. When Moderna reduced its booster dose from 100 to 50 micrograms, the signal diminished, lending further support to the dose connection.

What Antibody Studies Do and Don’t Tell You

Several studies compared the antibody levels generated by each vaccine, generally finding that Moderna produced higher levels of anti-spike antibodies. These results were often cited as evidence that Moderna was the “stronger” vaccine. But antibody studies have limitations that make them less straightforward than they seem.

One comparison of antibody responses in healthcare workers noted that the study lacked data on cellular immunity and neutralizing antibodies, and was limited to a specific professional population.⁶ Cellular immunity, the part of the immune system that involves T cells rather than circulating antibodies, plays a major role in preventing severe disease and death. Two vaccines could produce different antibody levels but similar T-cell responses, which would mean the antibody gap overstates the real-world protection gap.

Neutralizing antibodies, the subset that actually blocks the virus from entering cells, are more predictive of protection than total antibody levels. But measuring them is more complex and less commonly done in large-scale studies. So when you see headlines about one vaccine producing “more antibodies,” keep in mind that the measure most commonly reported is a rough proxy, not the whole story. The real-world effectiveness data, like the VA studies discussed earlier, capture the net effect of all immune responses combined and are more useful for comparing the two vaccines than antibody snapshots alone.

Age and Risk Shape Which Vaccine Makes More Sense

The picture that emerges from the evidence is not that one vaccine is universally better. It is that the balance of benefits and risks shifts depending on who is getting the shot. For older adults and people with conditions that put them at higher risk of severe COVID, Moderna’s slight effectiveness edge is the dominant consideration. The myocarditis risk in older populations is low with either vaccine, so the marginal benefit of Moderna’s stronger protection against hospitalization tilts the equation in its favor.

For adolescents and young men, the calculus flips. Their baseline risk of severe COVID is low, so the absolute benefit of the effectiveness gap is small. Meanwhile, the myocarditis risk differential is at its widest in this group. Several national advisory bodies in Europe and Canada recommended Pfizer over Moderna for younger populations precisely because of this age-dependent risk profile, even while acknowledging Moderna’s effectiveness advantage in older groups.

For healthy adults in their 30s through 50s, the two vaccines were functionally interchangeable for most practical purposes. The effectiveness difference, while real, was small enough that convenience, availability, and timing relative to a COVID surge mattered more than brand selection. If one was available and the other required a two-week wait, getting the available one sooner was almost certainly the better move.

Mixing and Matching Brands

As the pandemic progressed and people received multiple doses over time, many ended up with a mix of Moderna and Pfizer shots. This happened both by design, as some countries adopted mix-and-match booster policies, and by circumstance, when people received whichever vaccine was available at a given appointment. The general finding from studies of heterologous (mixed-brand) schedules was reassuring: mixing mRNA vaccines did not appear to compromise protection and in some cases may have produced a broader immune response than sticking with the same brand throughout.

This matters for people who received their primary series with one brand and later got a booster of the other. There is no need to worry about reduced protection from the mismatch. If anything, exposing the immune system to slightly different formulations of the same spike protein antigen may help train it to recognize a broader range of variants. The immune system responds to variety, and two different mRNA platforms delivering the same protein with slightly different packaging can serve as a form of that variety.

How Newer Formulations Changed the Comparison

As COVID-19 shifted from pandemic emergency to endemic circulation, both Moderna and Pfizer updated their vaccines to target newer variants. The original formulations that produced the most head-to-head data are no longer in use. Current shots target XBB or JN.1 lineages, and both companies have adjusted their mRNA content and delivery accordingly.

With each reformulation, the specific comparative data from the original vaccines becomes less directly applicable. The fundamental design differences persist: Moderna still uses a somewhat higher mRNA dose and different lipid nanoparticle technology. Whether the effectiveness and safety gaps observed with the original formulations hold at the same magnitude with updated versions is an ongoing question that newer studies will need to answer. Early data on the bivalent boosters suggested the pattern held, with Moderna showing a modest advantage against hospitalization.⁴ But whether that extends to monovalent XBB and JN.1 formulations remains to be confirmed in the same rigorous way.

For people scheduling their next annual COVID shot, the honest answer is that either vaccine remains a strong choice. The differences between them are small compared to the benefit of getting vaccinated at all, and the best vaccine is whichever one you can get at the right time relative to seasonal surges in your area. If you are in a higher-risk group and have a genuine choice between the two, the evidence accumulated so far slightly favors Moderna for durable protection, with the caveat that younger males should discuss the myocarditis signal with their provider.